Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 1.00 |
| ▸ | KCNK3 | O14649 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.70 |
| ▸ | CNR1 | P21554 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13151436 | 1.00 | CNR2 (1.00) | CNR2KCNK3ALDH1A1THRBBLM | |
| Methanandamide SCHEMBL27775277 | 1.00 | CNR2 (1.00) | CNR2KCNK3ALDH1A1THRBBLM | |
| Methanandamide SCHEMBL4236530 | 1.00 | CNR2 (1.00) | CNR2KCNK3ALDH1A1THRBBLM | |
| SCHEMBL31076313 | 0.92 | CNR2 (1.00) | CNR2KCNK3ALDH1A1THRBBLM | |
| SCHEMBL7620441 | 0.91 | CNR2 (0.83) | CNR2KCNK3ALDH1A1THRBBLM | |
| SCHEMBL4327695 | 0.91 | CNR2 (0.83) | CNR2KCNK3ALDH1A1THRBBLM | |
| SCHEMBL4320015 | 0.91 | CNR2 (0.83) | CNR2KCNK3ALDH1A1THRBBLM | |
| SCHEMBL7620584 | 0.91 | CNR2 (0.83) | CNR2KCNK3ALDH1A1THRBBLM | |
| SCHEMBL7617717 | 0.91 | CNR2 (0.83) | CNR2KCNK3ALDH1A1THRBBLM | |
| SCHEMBL7622699 | 0.91 | CNR2 (0.83) | CNR2KCNK3ALDH1A1THRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 566 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102502-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | UNIV JOHNS HOPKINS (US) | 2026-04-16 | — | — | US | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4577247-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | The Johns Hopkins University (US) | 2025-07-02 | — | — | EP | claimed |
| US-12194020-B2 | Reversing baldness through cannabinoid receptor activation | POSTREL RICHARD (US) | 2025-01-14 | — | — | US | claimed |
| US-20240408041-A1 | COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME | HABBOUSHE JOSEPH (US) | 2024-12-12 | — | — | US | claimed |
| CN-118641673-A | Application of ewe fecal metabolic marker in preparation of in vitro diagnostic reagent for early pregnancy of ewe | 兰州大学 | 2024-09-13 | — | — | CN | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024044776-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-29 | — | — | WO | claimed |
| WO-2023129818-A1 | GRANULAR COMPOSITION PROVIDING WATER DISPERSIBLE CANNABINOIDS AND METHODS OF MAKING THE SAME | PEGASUS LABORATORIES, INC. (US) | 2023-07-06 | — | — | WO | claimed |
| WO-2007047576-A1 | PHARMACOLOGICAL TREATMENTS FOR SLEEP DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-04-26 | — | — | WO | claimed |
| EP-1626724-A4 | METHOD AND KIT FOR REGULATION OF MICROVASCULAR TONE | UNIV TENNESSEE RES FOUNDATION (US) | 2006-10-04 | — | — | EP | claimed |
| EP-1037673-B1 | CHARGED LIPIDS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2006-08-23 | — | — | EP | claimed |
| EP-1626724-A2 | METHOD AND KIT FOR REGULATION OF MICROVASCULAR TONE | University of Tennessee Research Foundation (US) | 2006-02-22 | — | — | EP | claimed |
| US-20050137159-A1 | Methods compositions and articles of manufacture for modulating bone growth | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM | 2005-06-23 | — | — | US | claimed |
| WO-2004100867-A2 | METHOD AND KIT FOR REGULATION OF MICROVASCULAR TONE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2004-11-25 | — | — | WO | claimed |
| US-20040229850-A1 | Method and kit for regulation of microvascular tone | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE | 2004-11-18 | — | — | US | claimed |
| US-20040127572-A1 | Functional role for cannabinoids in autonomic stability during sleep | CARLEY DAVID W (US) | 2004-07-01 | — | — | US | claimed |
| EP-1372638-A1 | FUNCTIONAL ROLE FOR CANNABINOIDS IN AUTONOMIC STABILITY DURING SLEEP | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2002080903-A1 | FUNCTIONAL ROLE FOR CANNABINOIDS IN AUTONOMIC STABILITY DURING SLEEP | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2002-10-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137159-A1 | Methods compositions and articles of manufacture for modulating bone growth | BMP2, CNR1, CNR2 | CNR2 3/4885KCNK3 3813/4885ALDH1A1 3852/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR2 204/4885KCNK3 1901/4885ALDH1A1 1406/4885 |
| US-20260102502-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | CNR1, CNR2, GPR18 | CNR2 2/4885KCNK3 202/4885ALDH1A1 3449/4885 |
| US-20240408041-A1 | COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME | CNR2, TRPV1, CNR1 | CNR2 1/4885KCNK3 550/4885ALDH1A1 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.